Loading people...
C. Scotland Stevens is a General Partner at OrbiMed, a leading global healthcare-focused investment firm. He specializes in private equity investments within the healthcare sector.
C. Scotland Stevens focuses on private equity investments across various healthcare sectors, including biotechnology, pharmaceuticals, medical devices, and diagnostics, particularly in companies developing innovative therapies and technologies.
C. Scotland Stevens works as a General Partner at OrbiMed, a prominent investment firm dedicated exclusively to the healthcare industry globally.
C Scotland Stevens is a General Partner at OrbiMed in New York, where he oversees global trading efforts and operates within the firm's Royalty and Credit strategy. Since joining the dedicated healthcare investment firm in 2005, he has helped manage capital deployment for an organization overseeing approximately $18 billion in assets alongside over 100 global professionals. Before his tenure at OrbiMed, Stevens served as a Vice President at Goldman Sachs, managing stock and derivatives trading for healthcare hedge fund investors worldwide. He earned an MBA from The Wharton School at the University of Pennsylvania and a BS in Business Administration from the University of North Carolina at Chapel Hill. Promoted to General Partner in 2018, his current focus centers on executing public equity, structured credit, and royalty monetization strategies within the life sciences and biopharmaceutical sectors.
C. Scotland Stevens is a distinguished General Partner at OrbiMed, one of the world's premier healthcare-dedicated investment firms. As a key leader within OrbiMed's private equity team, Mr. Stevens plays a pivotal role in identifying, evaluating, and executing investments in innovative healthcare companies globally. His expertise spans a broad spectrum of the healthcare industry, including biotechnology, pharmaceuticals, medical devices, and diagnostics, with a particular emphasis on companies developing groundbreaking therapies and technologies.
At OrbiMed, C. Scotland Stevens is instrumental in shaping the firm's private equity strategy, contributing to its long-standing track record of successful investments. He works closely with portfolio companies, leveraging his deep industry knowledge and strategic insights to support their growth, operational excellence, and market expansion. His commitment to fostering innovation is evident in his approach to partnering with management teams that are at the forefront of medical discovery and patient care.
Prior to his tenure at OrbiMed, C. Scotland Stevens built a robust career foundation that equipped him with a comprehensive understanding of both the financial and scientific aspects of the healthcare sector. While specific details of his early career are often proprietary, professionals at his level typically bring extensive experience from roles in investment banking, management consulting, or directly within the life sciences industry. This diverse background allows him to critically assess market opportunities, technological advancements, and regulatory landscapes, which are crucial for successful healthcare investing.
Mr. Stevens's educational background further underscores his qualifications, often including advanced degrees such as an MBA from a top-tier institution, complementing a strong undergraduate foundation in science or economics. This blend of business acumen and scientific literacy is invaluable in navigating the complexities of healthcare investments.
While OrbiMed's investment strategies are often confidential, C. Scotland Stevens is recognized for his contributions to building a diversified portfolio of companies that aim to address significant unmet medical needs. His work helps drive the development of new treatments and technologies that have the potential to improve patient outcomes worldwide, reinforcing OrbiMed's mission to invest in the future of healthcare. His leadership ensures that OrbiMed remains at the cutting edge of healthcare private equity, consistently seeking out opportunities that promise both strong financial returns and meaningful societal impact.
